- Home
- RKLB vs EXEL Comparison
RKLB vs EXEL Comparison
Compare RKLB & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RKLB
- EXEL
- Stock Information
- Founded
- RKLB 2006
- EXEL 1994
- Country
- RKLB United States
- EXEL United States
- Employees
- RKLB N/A
- EXEL N/A
- Industry
- RKLB Aerospace
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RKLB Industrials
- EXEL Health Care
- Exchange
- RKLB Nasdaq
- EXEL Nasdaq
- Market Cap
- RKLB 12.3B
- EXEL 11.3B
- IPO Year
- RKLB N/A
- EXEL 2000
- Fundamental
- Price
- RKLB $35.65
- EXEL $43.79
- Analyst Decision
- RKLB Buy
- EXEL Buy
- Analyst Count
- RKLB 13
- EXEL 18
- Target Price
- RKLB $28.45
- EXEL $42.65
- AVG Volume (30 Days)
- RKLB 27.3M
- EXEL 3.5M
- Earning Date
- RKLB 08-07-2025
- EXEL 08-05-2025
- Dividend Yield
- RKLB N/A
- EXEL N/A
- EPS Growth
- RKLB N/A
- EXEL 237.58
- EPS
- RKLB N/A
- EXEL 2.20
- Revenue
- RKLB $466,016,000.00
- EXEL $2,298,922,000.00
- Revenue This Year
- RKLB $34.51
- EXEL $9.37
- Revenue Next Year
- RKLB $53.08
- EXEL $11.05
- P/E Ratio
- RKLB N/A
- EXEL $19.82
- Revenue Growth
- RKLB 64.98
- EXEL 24.49
- 52 Week Low
- RKLB $4.20
- EXEL $21.82
- 52 Week High
- RKLB $37.66
- EXEL $49.62
- Technical
- Relative Strength Index (RSI)
- RKLB 73.53
- EXEL 54.46
- Support Level
- RKLB $31.78
- EXEL $39.85
- Resistance Level
- RKLB $32.70
- EXEL $49.62
- Average True Range (ATR)
- RKLB 2.42
- EXEL 1.50
- MACD
- RKLB 0.69
- EXEL 0.06
- Stochastic Oscillator
- RKLB 90.61
- EXEL 33.52
About RKLB Rocket Lab USA Inc.
Rocket Lab USA Inc is engaged in space, building rockets, and spacecraft. It provides end-to-end mission services that provide frequent and reliable access to space for civil, defense, and commercial markets. It designs and manufactures the Electron and Neutron launch vehicles and Photon satellite platform. Rocket Lab's Electron launch vehicle has delivered multiple satellites to orbit for private and public sector organizations, enabling operations in national security, scientific research, space debris mitigation, Earth observation, climate monitoring, and communications. The business operates in two segments Launch Services and Space Systems. Geographically it serves Japan, Germany, rest of the world and earns key revenue from the United States.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.